Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WTX212A in advanced solid tumors
NCT06026605Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Aug 2023
- Primary completion
- Aug 2026
- Modality
- Antibody-Drug Conjugates (ADCs), Other Engineered Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of WTX212A in solid tumor (advanced stage), sponsored by Zhejiang University. Primary endpoints: Incidence of adverse events at 1 year, Incidence of treatment related adverse events at 1 year and 1 more. Started Aug 2023; status: recruiting.
02
Drugs
WTX212A
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06026605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06026605.